Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Performance Overview

For the cumulative third quarter period of the fiscal year ending March 2026, revenue increased 12.1% YoY to JPY 1,533.5 billion, supported by strong sales growth of key products Enhertu and Dato-Dowey. Core operating income rose 8.8% to JPY 249.2 billion, securing profit growth; however, operating income declined 5.9% to JPY 233.8 billion due to one-time revenue declines and loss compensation recorded for contract manufacturers. Net income attributable to owners of the parent for the quarter rose 4.2% to JPY 217.4 billion, reflecting reduced corporate tax expenses.

Segment Performance and Research & Development Status

The Japan Business Unit recorded revenue of JPY 390.8 billion, up 1.3% YoY; Daiichi Sankyo Healthcare Unit grew 4.7% to JPY 70.6 billion; Oncology Business Unit increased 30.3% to JPY 439.2 billion; ASCA Business Unit rose 20.8% to JPY 187.2 billion. R&D expenses increased 12.7% to JPY 338.7 billion, with enhanced investments particularly in 5DXd ADCs (such as Enhertu and Dato-Dowey). Multiple clinical trials are underway, progress includes FDA Breakthrough Therapy designations and regulatory filings and approvals in various countries.

Financial Position and Shareholder Returns

Total assets stood at JPY 3,821.8 billion, total liabilities at JPY 2,111.3 billion, and total equity at JPY 1,710.5 billion, resulting in an equity ratio attributable to owners of the parent of 44.8%, a decline from the previous fiscal year-end. Shareholder returns included a forecast annual dividend for fiscal 2025 of JPY 78 (an increase of JPY 18 YoY) and an interim dividend of JPY 39. The company is actively conducting share buybacks, establishing a repurchase program from April 2025 to March 2026 with a ceiling of JPY 200 billion or 80 million shares.